The results of the latest clinical trial studies have also shown that the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) are significantly higher in T2DM patients than in normal subjects [81]. This evidence concerns the gene IL6 and type 2 diabetes mellitus.